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Abstract
Background: A positive tuberculin skin test (TST) is often defined by skin induration of ≥10 mm in people who are
HIV-seronegative. However, to increase sensitivity for detection of Mycobacterium tuberculosis infection in the
context of impaired immune function, a revised cut-off of ≥5 mm is used for people living with HIV infection. The
incremental proportion of patients who are included by this revised definition and the association between this
proportion and CD4+ cell count are unknown.
Methods: The literature was systematically reviewed to determine the proportion of people living with HIV
(PLWH) without evidence of active tuberculosis in low and middle-income countries who tested TST-positive
using cut-offs of ≥5 mm and ≥10 mm of induration. The difference in the proportion testing TST-positive
using the two cut-off sizes was calculated for all eligible studies and was stratified by geographical region
and CD4+ cell count.
Results: A total of 32 studies identified meeting criteria were identified, providing data on 10,971 PLWH from
sub-Saharan Africa, Asia and the Americas. The median proportion of PLWH testing TST-positive using a
cut-off of ≥5 mm was 26.8% (IQR, 19.8-46.1%; range, 2.5-81.0%). Using a cut-off of ≥10 mm, the median
proportion of PLWH testing TST-positive was 19.6% (IQR, 13.7-36.8%; range 0–52.1%). The median difference in
the proportion of PLWH testing TST-positive using the two cut-offs was 6.0% (IQR, 3.4-10.1%; range, 0–37.6%).
Among those with CD4+ cell counts of <200, 200–499 and ≥500 cells/μL, the proportion of positive tests
defined by the ≥5 mm cut-off that were between 5.0 and 9.9 mm in diameter was similar (12.5%, 12.9% and
10.5%, respectively).
Conclusions: There is a small incremental yield in the proportion of PLWH who test TST-positive when using
an induration cut-off size of ≥5 mm compared to ≥10 mm. This proportion was similar across the range of
CD4+ cell strata, supporting the current standardization of this cut-off at all levels of immunodeficiency.
Keywords: HIV, Tuberculin skin test, TST, Tuberculosis, CD4
* Correspondence: andrewkerkhoff@gmail.com
1School of Medicine and Health Sciences, The George Washington University,
Washington, DC, USA
2Desmond Tutu HIV Centre, Institute of Infectious Disease andMolecular Medicine,
Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
Full list of author information is available at the end of the article
© 2013 Kerkhoff et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Kerkhoff et al. BMC Infectious Diseases 2013, 13:307
http://www.biomedcentral.com/1471-2334/13/307
Background
Tuberculin skin tests (TSTs) have for a long time been
used to define likely Mycobacterium tuberculosis (MTB)
infection, identify those who may benefit from isoniazid
preventive therapy and aid diagnosis of tuberculosis
(TB) disease, especially in children. While interferon
gamma release assays (IGRAs) were developed to im-
prove the diagnostic accuracy for MTB infection, the
World Health Organization (WHO) does not recom-
mend routine use of IGRAs in resource limited settings
due to cost, technical complexity and limited utility [1].
The sensitivity of TSTs for detecting MTB infection is
impaired among people living with HIV (PLWH) due to
an attenuation of cell-mediated responses, including a
reduction in memory CD4+ T cells at the TST site [2].
While a cut-off of ≥10 mm of induration is often used to
define a positive TST among those who are HIV sero-
negative, a cut-off of ≥5 mm is instead recommended by
the US Centers for Disease Control and Prevention
among PLWH to increase the sensitivity [3]. This revised
cut-off is based on unpublished data from New York
City in the 1980’s among just 23 AIDS patients with
known TB disease of whom two had a TST of 5–9 mm
induration while 13 had an induration ≥10 mm [4].
However, the incremental proportion of individuals de-
fined as TST-positive when using this revised cut-off and
the variables such as CD4+ cell count that might be as-
sociated with this proportion are not known.
Cobelens and colleagues [5] investigated TST re-
sponses among a large number of PLWH who were di-
agnosed as having active smear-positive pulmonary
tuberculosis (TB) in Tanzania. Although just 71.2% of
patients tested TST-positive when using the recom-
mended cut-off of ≥5 mm of induration, this did not
differ substantially from the proportion defined as posi-
tive using a cut-off of ≥10 mm of induration (64.3%)
with a difference of just 6.9%. Thus, the altered cut-off
only marginally reduced the number of false-negative
tests. The authors concluded from their data that loss of
sensitivity of the TST in PLWH is predominantly attri-
butable to anergy (ie an all-or-nothing phenomenon) ra-
ther than due to a gradual diminution in TST diameter
during progressive immunodeficiency. However, this
study was conducted solely among PLWH who had
active TB and these findings cannot necessarily be ex-
trapolated to those with latent MTB infection and any
association with CD4+ cell count was not defined.
We previously conducted a systematic review of the lit-
erature to ascertain the proportions of PLWH who tested
TST-positive using the conventional cut-off of ≥5 mm of
induration [6]. In the present systematic review, we deter-
mined the proportions of PLWH testing TST-positive
using cut-offs of ≥5 mm and ≥10 mm cut-off and the rela-
tionship with CD4+ cell count.
Methods
Search strategy
The search strategy has been described in detail else-
where [6]. In brief, we searched Embase, Global Health,
Medline and Web of Science for relevant citations using
a combination of MeSH and free text search terms
according to a predetermined search criteria. The search
was restricted to articles from January 1, 1990 to Febru-
ary 5, 2012 as an initial search demonstrated no relevant
citations prior to this period. The first search set was
created using comprehensive search terms for tuberculin
skin test, latent tuberculosis and isoniazid preventive
therapy and were combined using “or.” A second set was
created for HIV/AIDS using comprehensive search
terms. These two sets were then combined using “and.”
Next, this set was combined with a low and middle-
income country (LMIC) set (using the World Bank list
of economies as of 01 July 2011) [7] using “and.” All ci-
tations were then limited to articles published in English
and among humans.
Studies eligible for inclusion were those that were
conducted in LMIC’s, included only PLWH who were at
least 15 years of age, presented data for patients without
evidence of active TB disease, and presented the propor-
tion of those testing TST-positive current using a indur-
ation cut-off size of both ≥5 mm and ≥10 mm. Studies
were also required to have at least 30 participants meet-
ing the above criteria to limit imprecision around the
point estimates. Studies utilizing two-step TST testing
were excluded. All studies meeting the aforementioned
criteria were included regardless of patient ART status at
enrolment.
Citations identified through the search process were
compiled into Endnote where duplicate citations were
removed. Titles and abstracts were screened for study
inclusion. Potentially relevant full-text citations were
entered into an Excel spreadsheet and the full-texts were
obtained. Two readers (ADK and SDL) carefully re-
viewed all full-text publications for study inclusion.
Additional studies met the inclusion criteria following
provision of additional data by the authors as previously
described [6].
Data extraction
Study characteristics from eligible studies were abstracted
directly into a structured Microsoft Excel spreadsheet.
Variables recorded included: title, authors, year of publica-
tion, study period, study location, clinical setting, mean or
median patient age, bacille Calmette et Guerin (BCG)
vaccine scar status, ART status, special or potentially non-
generalizable populations and the total number of eligible
PLWH who underwent TST testing (and returned to have
their results read) and the total number PLWH testing
TST-positive using both a ≥5 mm and a ≥10 mm
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induration size. When TST-results using both a ≥5 mm
and a ≥10 mm cut-off stratified by CD4+ cell counts
(<200, 200–499 and ≥500 cells/μL) were available, these
were also recorded.
The quality of studies was independently assessed by
two reviewers (ADK and SDL) using a graded checklist
[6]. A study receiving 70% of available points was con-
sidered to be of “good quality”, 50-70% was considered
“medium quality” and less than 50% was considered
“lower quality.” We also assessed the risk of bias in indi-
vidual studies as well as across all included studies.
Statistical analysis
All statistical analysis was completed using STATA version
10.0. The difference in the proportion of those testing
TST-positive using a ≥5 mm versus a ≥10 mm cut-off was
calculated for all eligible studies and chi-squared tests
were used to compare these proportions. Differences in
the proportions of PLWH testing TST-positive by each
cut-off size were then plotted using a forest plot and were
stratified by geographic region and CD4+ cell count.
Pooled estimates of overall data or stratified data were not
derived due to substantial heterogeneity between studies
as indicated by large I2 values [8].
Results
Of the 3,095 potential citations identified in the literature
search, 254 were selected for full-text review (Figure 1).
After concluding a full-text review, 24 articles met the
pre-defined inclusion criteria and an additional 8 articles
met inclusion criteria due to unpublished data provided
by authors for a previous study. In all, 32 publications
provided data from 34 unique study populations and
were published between 1992 and 2011 (Additional file 1).
Among included publications, 14 study populations were
from Africa, 8 from the Americas and 12 from Asia. The
TB prevalence in counties in which the studies were
conducted ranged from 0.19-785 cases per 100,000 popu-
lation and the majority (62%; 21/34) of study populations
were from high-prevalence TB countries (estimated TB
prevalence >100 cases per 100,000 population).
The mean/median age among patients in eligible stud-
ies ranged from 22–42 years. The proportions of PLWH
on ART at the time of TST assessment was reported for
18 study populations and an additional six study popula-
tions were assumed to be ART naïve as the studies were
conducted prior to national ART implementation. Among
these 24 populations, ART was received by a proportion
of the participants in only 9 studies and this proportion
varied from 1% to 100% (median 58%). Nine publications
were of high quality, 12 studies of medium quality and 11
studies of low quality, as determined by a quality assess-
ment checklist.
Difference in patients testing TST-positive using a ≥5 mm
versus ≥10 mm cut-off size
Overall, there were 10,971 PLWH with TST results from
34 study populations; 4,880 were from sub-Saharan
Africa, 2,247 from the Americas and 3,844 from Asia.
All studies reported the proportion of individuals testing
TST-positive using both a 5 mm and 10 mm cut-off
(Table 1).
The median proportion of PLWH testing TST-positive
using a cut-off of ≥5 mm was 26.8% (IQR, 19.8-46.1%;
range 2.5-81.0%). There was considerable heterogeneity
with regard to regional differences in the proportion of
Figure 1 Overview of eligible studies containing data on the proportion of people living with HIV testing TST-positive using a ≥5 mm
and ≥10 mm cut-off size.
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patients testing TST-positive. The median proportions
of patients testing TST-positive in sub-Saharan Africa,
the Americas and Asia were 36.8% (IQR, 24.7-51.0%;
range, 20.2-57.5%), 17.8% (IQR, 10.6-22.9%; range, 2.5-
58.1%), and 27.3% (IQR, 20.3-45.8%; range, 3.2-81.0%),
respectively.
When a cut-off of ≥10 mm was used, the median pro-
portion of patients testing TST-positive was 19.6% (IQR,
Table 1 The proportion of people living with HIV who tested TST-positive using a ≥5 mm and ≥10 mm cutoff size and
the difference between these two proportions
Study Number ofpatients (n)
Number of patients
TST-positive using
≥5 mm cut-off (%)
Number of patients
TST-positive using
≥10 mm cut-off (%)
Difference in proportion
of patients testing
TST-positive (%)
P-value
Africa
Allen et al. [9] 284 73 (25.7) 60 (21.1) 4.6 0.1977
Aisu et al. [10] 1094 579 (52.9) 376 (34.4) 18.6 <0.0001
Duncan et al. [11] 106 35 (33.0) 32 (30.2) 2.8 0.6576
Fordham von Reyn et al. [12] 104 21 (20.2) 20 (19.2) 1.0 0.8616
Diagbouga et al. [13] 37 9 (24.3) 6 (16.2) 1.7 0.3857
Waddell et al. [14] 58 16 (27.6) 15 (25.9) 8.1 0.8338
Mtei et al. [15] 460 192 (41.7) 175 (38.0) 3.7 0.2524
Tegbaru et al. [16] 116 47 (40.5) 38 (32.8) 7.8 0.2201
Rangaka et al. [17] 67 35 (52.2) 33 (49.3) 3.0 0.7297
Karam et al. [18] 273 59 (21.6) 46 (16.8) 4.8 0.1581
Hanifa et al. [19] 33 18 (54.5) 14 (42.4) 12.1 0.3245
Leidl et al. [20] 89 42 (47.2) 35 (39.3) 7.9 0.2896
Oni et al. [21] 240 138 (57.5) 125 (52.1) 5.4 0.2332
Samandari et al. [22] 1919 468 (24.4) 383 (20.0) 4.4 0.0010
The Americas
Espinal et al. [23] 86 50 (58.1) 40 (46.5) 11.6 0.1269
Fordham von Reyn et al. [12] 121 3 (2.5) 2 (1.7) 0.8 0.6513
Garcia-Garcia et al. [24] 801 261 (32.6) 174 (21.7) 10.9 <0.0001
Miranda et al. [25] 98 16 (16.3) 12 (12.2) 4.6 0.4142
Balcells et al. [26] 109 12 (11.0) 7 (6.4) 4.1 0.2299
Gutierrez et al. [27] 104 20 (19.2) 13 (12.5) 6.7 0.184
Baboolal et al. [28] 64 6 (9.4) 0 9.4 0.0121
Moura et al. [29] 864 170 (19.7) 152 (17.6) 2.1 0.2661
Asia
Suwanagool et al. [30] 399 323 (81.0) 173 (43.4) 37.6 <0.0001
Yanai et al. [31] 217 46 (21.2) 32 (14.7) 6.5 0.0801
Yanai et al. [31] 129 21 (16.3) 15 (11.6) 4.7 0.281
Sawhney et al. [32] 396 103 (26.0) 62 (15.7) 10.4 0.0003
Gupta et al. [33] 752 157 (20.9) 137 (18.2) 2.7 0.1935
Swaminathan et al. [34] 631 269 (42.6) 227 (36.0) 6.7 0.0155
Davarpanah et al. [35] 173 64 (37.0) 23 (13.3) 23.7 <0.0001
Davarpanah et al. [36] 459 131 (28.5) 60 (13.1) 15.5 <0.0001
Jiang et al. [37] 46 27 (58.7) 17 (37.0) 21.7 0.0369
Zhang et al. [38] 93 3 (3.2) 3 (3.2) 0 1
Kabeer et al. [39] 180 33 (18.3) 27 (15.0) 3.3 0.3961
Nguyen et al. [40] 369 204 (55.3) 175 (47.4) 8.1 0.0274
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Figure 2 Forest plot showing the difference in proportions (%, 95% CI) of people living with HIV testing TST-positive using a ≥5 mm
versus a ≥10 mm cut-off size in (a) all study populations (n = 34) and (b) with data grouped according to region.
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Table 2 The proportion of people living with HIV who tested TST-positive using a ≥5 mm and ≥10 mm cutoff size stratified by CD4+ cell count categories
<200, ≥200, 200–499 and ≥500 cells/μL
Study
Number of
patients with
CD4+ cell
count <200
Number of
patients TST
positive using
≥5 mm cutoff (%)
Number of
patients TST
positive using
≥10 mm cutoff (%)
Number of
patients with
CD4+ cell
count 200-499
Number of
patients TST
positive using
≥5 mm cutoff (%)
Number of
patients TST
positive using
≥10 mm cutoff (%)
Number of
patients with
CD4+ cell
count ≥500
Number of
patients TST
positive using
≥5 mm cutoff (%)
Number of
patients TST
positive using
≥10 mm cutoff (%)
Gupta et al. [33] 50 8 (16.0) 7 (14.0) 326 71 (21.8) 66 (20.2) 307 65 (21.2) 56 (18.2)
Rangaka et al. [17] 8 2 (25.0) 2 (25.0) 31 17 (54.8) 16 (51.6) 18 11 (61.1) 10 (55.6)
Karam et al. [18] 145 11 (7.6) 10 (6.9) 85 25 (29.4) 22 (25.9) 43 23 (53.5) 14 (32.6)
Balcells et al. [26] 13 1 (7.7) 1 (7.7) 73 4 (5.5) 2 (2.7) 23 7 (30.4) 4 (17.4)
Swaminathan et al. [34] 150 64 (42.7) 48 (32.0) 313 138 (44.1) 117 (37.4) 160 67 (41.9) 62 (38.8)
Moura et al. [29] 137 13 (9.5) 13 (9.5) 386 70 (18.1) 61 (15.8) 341 87 (25.5) 78 (22.9)
Nguyen et al. [40] 75 31 (41.3) 24 (32.0) 206 116 (56.3) 100 (48.5) 88 57 (64.8) 51 (58.0)
Oni et al. [21] 51 25 (49.0) 21 (41.2) 137 79 (57.7) 73 (53.3) 50 33 (66.0) 30 (60.0)
Samandari et al. [22] 575 88 (15.3) 74 (12.9) 952 250 (26.3) 212 (22.3) 364 124 (34.1) 93 (25.6)
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13.7-36.8%; range, 0–52.1%). Strong regional differences
in the proportion of patients TST-positive were again
noted. Patients in sub-Saharan Africa had a median
TST-positive proportion of 31.5% (IQR, 20.3-39.0%;
range, 16.2-52.1%) compared to 12.4% (IQR, 5.2-18.6%;
range, 0–46.5%) in the Americas and 15.4% (IQR, 13.3-
36.3%; range, 3.2-47.4%) in Asia.
The median difference observed in the proportion of
those testing TST-positive using a cut-off size of ≥5 mm
versus ≥10 mm was 6.0% (IQR, 3.4-10.1%; range 0–
37.6%). When stratified by geographic region, the me-
dian difference in the proportion of patients testing
TST-positive using a 5 mm versus a 10 mm cut-off was
4.7% (IQR, 3.1-7.9%, range, 1.0-18.6%), 5.7% (IQR, 3.6-
9.8%, range, 0.8-11.6%) and 7.3% (IQR, 4.4-17.0%, range,
0–37.6%) for Africa, the Americas and Asia respectively.
The overall difference in the proportions of patients
testing TST positive (Figure 2a) and stratified according
to geographic region (Figure 2b) was demonstrated in
forest plots.
Association with CD4+ cell counts
Nine studies with a total of 5,107 PLWH reported the pro-
portion of those testing TST-positive using both a ≥5 mm
and a ≥10 mm cut-off size stratified by CD4+ cell counts
at <200, 200–499, ≥500 (Table 2). These CD4+ cell count
stratified data are shown in a forest plot (Figure 3). The
median difference in the proportion of PLWH testing
TST-positive using the two induration cut-off sizes was
2.0% (range, 0–10.7%; IQR, 0–7.8%), 3.5% (range, 1.5-
7.8%; IQR, 2.7-4.4%) and 6.0% (range, 2.6-20.9%; IQR, 4.9-
9.6%) among those with CD4+ cell counts <200, 200–499,
≥500 cells/μL, respectively. The corresponding propor-
tions of positive tests defined by the ≥5 mm cut-off that
were between 5.0 and 9.9 mm in diameter were 12.5%
(IQR, 0–16.0), 12.9% (IQR, 7.6-15.2), 10.5% (IQR, 9.1-
28.5), respectively [9-40].
Discussion
This study found that among 10,971 patients without ac-
tive TB in 34 different study populations, the incremen-
tal yield of patients defined as TST-positive when using
a ≥5 mm cut-off rather than a ≥10 mm cut-off was just
6.0%. This suggests that using the modified cut-off had
only a modest effect on increasing the proportion of
PLWH who tested TST-positive. Importantly, this pro-
portion was similar across the range of CD4+ cell count
strata and also across different geographic regions.
Figure 3 Forest plot showing the difference in proportions (%, 95% CI) of people living with HIV testing TST-positive using a ≥5 mm
versus a ≥10 mm cut-off size with data grouped according to CD4+ cell count strata (<200, 200–499 and ≥500 cells/μL).
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Our findings of a 6% incremental proportion associated
with the use of the revised TST cut-off among patients
without active TB are very similar to those of Cobelens
and colleagues [5] who reported a 7% increment among
patients with active TB in Tanzania. This suggests that the
small differences observed in the proportion of PLWH
testing TST-positive using the two cut-off sizes are
generalizable regardless of TB infection or disease status.
A recent systematic review and meta-analysis [41] in-
vestigated the utility of ≥5 mm and ≥10 mm TST cut-off
sizes to predict the progression from latent infection to
active TB disease. Among five studies in which the HIV
status of patients was largely unknown, the unadjusted
incidence rate ratio of tuberculosis in TST-positive
patients was 1.43 (95% CI, 0.75-2.72) when a cut-off of
≥5 mm was used and 1.60 (95% CI, 0.94-2.72) when a
cut-off ≥10 mm was applied. Thus, neither cut-off size
better predicted the risk for progression to active TB
disease. However, because the HIV status of the patients
included in these studies was negative or largely un-
known, it remains unclear whether these findings are
generalizable to PLWH.
TSTs rather than IGRAs are the WHO-recommended
assay for use in LMICs for detecting latent tuberculosis
infection among PLWH prior to isoniazid preventive
therapy [42]. Although use of TST is recommended, it
remains unknown whether a ≥5 mm or ≥10 mm cut-off
size better defines those who will benefit from IPT. A
meta-analysis [43] among PLWH demonstrated that
among those with a TST induration of ≥5 mm in diam-
eter, IPT was associated with a TB risk reduction of 64%
(95% CI, 39-78 %). However, all studies in this meta-
analysis defined TST-positivity using a ≥5 mm cut-off
size and thus it is not known whether those with a 5.0-
9.9 mm induration gain benefit from IPT. An individual
patient meta-analysis of data from randomized trials of
isoniazid preventive therapy may be able to define this.
Strengths of this study include a comprehensive search
strategy that utilized four different study databases. There
were more than 10,000 patients from 34 unique study
populations from many countries and geographic regions.
Also, a number of variables potentially influencing differ-
ences in the proportion of TST-positive patients were
recorded and summarized where possible. There were also
several limitations. The reliability of TST assessment could
not be assessed. Additionally, methods for excluding TB
disease were not standardized among included studies.
Heterogeneity in the data precluded the calculation of
pooled summary estimates.
Conclusion
In conclusion, using a ≥5 mm cut-off among PLWH
resulted in only a modest increase in the proportion test-
ing TST-positive when compared to a cut-off size of
≥10 mm and this finding concurs with a similar study that
was conducted among patients with active TB. The differ-
ence in the proportion of PLWH testing TST-positive
when using the two different cut-off sizes was similar
across the range of CD4+ cell count strata suggesting use
of this cut-off across the spectrum of immunodeficiency.
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